The Experts below are selected from a list of 7035 Experts worldwide ranked by ideXlab platform

Kenji Yamazaki - One of the best experts on this subject based on the ideXlab platform.

  • Histological maturation of vascular smooth muscle cells in in situ tissue-engineered vasculature.
    Biomaterials, 2014
    Co-Authors: Noriko Isayama, Goki Matsumura, Hideki Sato, Shojiro Matsuda, Kenji Yamazaki
    Abstract:

    The goal of regenerative medicine is to achieve histological and functional recovery to the level of the original tissue. For this purpose, we have developed a Biodegradable Scaffold to create cell-free in-situ tissue-engineered vasculature (iTEV) with good long-term results. However, the regeneration process of vascular smooth muscle cells (VSMCs) over time has yet to be examined. To evaluate the regeneration ability of VSMCs, the inferior vena cava of experimental animals was replaced with iTEV, and tested at 1, 3, 6, 12, and 24 months (n = 6 each) after implantation. Six animals were enrolled to compare 24-month iTEV and native vasculature in single individual samples. There were no complications throughout the study. Immunohistology, protein expression analysis, and biochemical findings indicate that iTEV can gradually regenerate and develop into a mature vessel within 24 months using our Biodegradable Scaffold. These results provide a time course for the regeneration of VSMCs within the tissue-engineered vascular autograft constructed using a Biodegradable Scaffold.

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue engineering of pulmonary artery in a canine model
    Biomaterials, 2013
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kensuke Taki, Kenji Yamazaki
    Abstract:

    We previously developed a cell-free, Biodegradable Scaffold for in-situ tissue-engineering vasculature (iTEV) in a canine inferior vena cava (IVC) model. In this study, we investigated application of this Scaffold for iTEV of the pulmonary artery (iTEV-PA) in a canine model. In vivo experiments were conducted to determine Scaffold characteristics and long-term efficacy. Biodegradable Scaffolds comprised polyglycolide knitted fibers and an l-lactide and e-caprolactone copolymer sponge, with an outer glycolide and e-caprolactone copolymer monofilament reinforcement. Tubular Scaffolds (8 mm diameter) were implanted into the left pulmonary artery of experimental animals (n = 7) and evaluated up to 12 months postoperatively. Angiography of iTEV-PA after 12 months showed a well-formed vasculature without marked stenosis, aneurysmal change or thrombosis of iTEV-PA. Histological analysis revealed a vessel-like vasculature without calcification. However, vascular smooth muscle cells were not well-developed 12 months post-implantation. Biochemical analyses showed no significant difference in hydroxyproline and elastin content compared with native PA. Our long-term results of cell-free tissue-engineering of PAs have revealed the acceptable qualities and characteristics of iTEV-PAs. The strategy of using this cell-free Biodegradable Scaffold to create relatively small PAs could be applicable in pediatric cardiovascular surgery requiring materials.

  • Abstract 13153: Long-Term Results of Cell-Free Biodegradable Scaffolds for In Situ Tissue-Engineering Pulmonary Artery in a Canine Model
    Circulation, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kenji Yamazaki
    Abstract:

    We have previously developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV) in a canine IVC model. We assessed the hy...

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model.
    PloS one, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.51±0.19 mmHg. The length of the iTEV at 2 years had increased by 0.48±0.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascular surgery involving biocompatible materials.

  • Longterm results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
    2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90 % of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascula

Goki Matsumura - One of the best experts on this subject based on the ideXlab platform.

  • Histological maturation of vascular smooth muscle cells in in situ tissue-engineered vasculature.
    Biomaterials, 2014
    Co-Authors: Noriko Isayama, Goki Matsumura, Hideki Sato, Shojiro Matsuda, Kenji Yamazaki
    Abstract:

    The goal of regenerative medicine is to achieve histological and functional recovery to the level of the original tissue. For this purpose, we have developed a Biodegradable Scaffold to create cell-free in-situ tissue-engineered vasculature (iTEV) with good long-term results. However, the regeneration process of vascular smooth muscle cells (VSMCs) over time has yet to be examined. To evaluate the regeneration ability of VSMCs, the inferior vena cava of experimental animals was replaced with iTEV, and tested at 1, 3, 6, 12, and 24 months (n = 6 each) after implantation. Six animals were enrolled to compare 24-month iTEV and native vasculature in single individual samples. There were no complications throughout the study. Immunohistology, protein expression analysis, and biochemical findings indicate that iTEV can gradually regenerate and develop into a mature vessel within 24 months using our Biodegradable Scaffold. These results provide a time course for the regeneration of VSMCs within the tissue-engineered vascular autograft constructed using a Biodegradable Scaffold.

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue engineering of pulmonary artery in a canine model
    Biomaterials, 2013
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kensuke Taki, Kenji Yamazaki
    Abstract:

    We previously developed a cell-free, Biodegradable Scaffold for in-situ tissue-engineering vasculature (iTEV) in a canine inferior vena cava (IVC) model. In this study, we investigated application of this Scaffold for iTEV of the pulmonary artery (iTEV-PA) in a canine model. In vivo experiments were conducted to determine Scaffold characteristics and long-term efficacy. Biodegradable Scaffolds comprised polyglycolide knitted fibers and an l-lactide and e-caprolactone copolymer sponge, with an outer glycolide and e-caprolactone copolymer monofilament reinforcement. Tubular Scaffolds (8 mm diameter) were implanted into the left pulmonary artery of experimental animals (n = 7) and evaluated up to 12 months postoperatively. Angiography of iTEV-PA after 12 months showed a well-formed vasculature without marked stenosis, aneurysmal change or thrombosis of iTEV-PA. Histological analysis revealed a vessel-like vasculature without calcification. However, vascular smooth muscle cells were not well-developed 12 months post-implantation. Biochemical analyses showed no significant difference in hydroxyproline and elastin content compared with native PA. Our long-term results of cell-free tissue-engineering of PAs have revealed the acceptable qualities and characteristics of iTEV-PAs. The strategy of using this cell-free Biodegradable Scaffold to create relatively small PAs could be applicable in pediatric cardiovascular surgery requiring materials.

  • Abstract 13153: Long-Term Results of Cell-Free Biodegradable Scaffolds for In Situ Tissue-Engineering Pulmonary Artery in a Canine Model
    Circulation, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kenji Yamazaki
    Abstract:

    We have previously developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV) in a canine IVC model. We assessed the hy...

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model.
    PloS one, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.51±0.19 mmHg. The length of the iTEV at 2 years had increased by 0.48±0.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascular surgery involving biocompatible materials.

  • Longterm results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
    2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90 % of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascula

Noriko Isayama - One of the best experts on this subject based on the ideXlab platform.

  • Histological maturation of vascular smooth muscle cells in in situ tissue-engineered vasculature.
    Biomaterials, 2014
    Co-Authors: Noriko Isayama, Goki Matsumura, Hideki Sato, Shojiro Matsuda, Kenji Yamazaki
    Abstract:

    The goal of regenerative medicine is to achieve histological and functional recovery to the level of the original tissue. For this purpose, we have developed a Biodegradable Scaffold to create cell-free in-situ tissue-engineered vasculature (iTEV) with good long-term results. However, the regeneration process of vascular smooth muscle cells (VSMCs) over time has yet to be examined. To evaluate the regeneration ability of VSMCs, the inferior vena cava of experimental animals was replaced with iTEV, and tested at 1, 3, 6, 12, and 24 months (n = 6 each) after implantation. Six animals were enrolled to compare 24-month iTEV and native vasculature in single individual samples. There were no complications throughout the study. Immunohistology, protein expression analysis, and biochemical findings indicate that iTEV can gradually regenerate and develop into a mature vessel within 24 months using our Biodegradable Scaffold. These results provide a time course for the regeneration of VSMCs within the tissue-engineered vascular autograft constructed using a Biodegradable Scaffold.

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue engineering of pulmonary artery in a canine model
    Biomaterials, 2013
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kensuke Taki, Kenji Yamazaki
    Abstract:

    We previously developed a cell-free, Biodegradable Scaffold for in-situ tissue-engineering vasculature (iTEV) in a canine inferior vena cava (IVC) model. In this study, we investigated application of this Scaffold for iTEV of the pulmonary artery (iTEV-PA) in a canine model. In vivo experiments were conducted to determine Scaffold characteristics and long-term efficacy. Biodegradable Scaffolds comprised polyglycolide knitted fibers and an l-lactide and e-caprolactone copolymer sponge, with an outer glycolide and e-caprolactone copolymer monofilament reinforcement. Tubular Scaffolds (8 mm diameter) were implanted into the left pulmonary artery of experimental animals (n = 7) and evaluated up to 12 months postoperatively. Angiography of iTEV-PA after 12 months showed a well-formed vasculature without marked stenosis, aneurysmal change or thrombosis of iTEV-PA. Histological analysis revealed a vessel-like vasculature without calcification. However, vascular smooth muscle cells were not well-developed 12 months post-implantation. Biochemical analyses showed no significant difference in hydroxyproline and elastin content compared with native PA. Our long-term results of cell-free tissue-engineering of PAs have revealed the acceptable qualities and characteristics of iTEV-PAs. The strategy of using this cell-free Biodegradable Scaffold to create relatively small PAs could be applicable in pediatric cardiovascular surgery requiring materials.

  • Abstract 13153: Long-Term Results of Cell-Free Biodegradable Scaffolds for In Situ Tissue-Engineering Pulmonary Artery in a Canine Model
    Circulation, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kenji Yamazaki
    Abstract:

    We have previously developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV) in a canine IVC model. We assessed the hy...

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model.
    PloS one, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.51±0.19 mmHg. The length of the iTEV at 2 years had increased by 0.48±0.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascular surgery involving biocompatible materials.

  • Longterm results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
    2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90 % of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascula

Shojiro Matsuda - One of the best experts on this subject based on the ideXlab platform.

  • Histological maturation of vascular smooth muscle cells in in situ tissue-engineered vasculature.
    Biomaterials, 2014
    Co-Authors: Noriko Isayama, Goki Matsumura, Hideki Sato, Shojiro Matsuda, Kenji Yamazaki
    Abstract:

    The goal of regenerative medicine is to achieve histological and functional recovery to the level of the original tissue. For this purpose, we have developed a Biodegradable Scaffold to create cell-free in-situ tissue-engineered vasculature (iTEV) with good long-term results. However, the regeneration process of vascular smooth muscle cells (VSMCs) over time has yet to be examined. To evaluate the regeneration ability of VSMCs, the inferior vena cava of experimental animals was replaced with iTEV, and tested at 1, 3, 6, 12, and 24 months (n = 6 each) after implantation. Six animals were enrolled to compare 24-month iTEV and native vasculature in single individual samples. There were no complications throughout the study. Immunohistology, protein expression analysis, and biochemical findings indicate that iTEV can gradually regenerate and develop into a mature vessel within 24 months using our Biodegradable Scaffold. These results provide a time course for the regeneration of VSMCs within the tissue-engineered vascular autograft constructed using a Biodegradable Scaffold.

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue engineering of pulmonary artery in a canine model
    Biomaterials, 2013
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kensuke Taki, Kenji Yamazaki
    Abstract:

    We previously developed a cell-free, Biodegradable Scaffold for in-situ tissue-engineering vasculature (iTEV) in a canine inferior vena cava (IVC) model. In this study, we investigated application of this Scaffold for iTEV of the pulmonary artery (iTEV-PA) in a canine model. In vivo experiments were conducted to determine Scaffold characteristics and long-term efficacy. Biodegradable Scaffolds comprised polyglycolide knitted fibers and an l-lactide and e-caprolactone copolymer sponge, with an outer glycolide and e-caprolactone copolymer monofilament reinforcement. Tubular Scaffolds (8 mm diameter) were implanted into the left pulmonary artery of experimental animals (n = 7) and evaluated up to 12 months postoperatively. Angiography of iTEV-PA after 12 months showed a well-formed vasculature without marked stenosis, aneurysmal change or thrombosis of iTEV-PA. Histological analysis revealed a vessel-like vasculature without calcification. However, vascular smooth muscle cells were not well-developed 12 months post-implantation. Biochemical analyses showed no significant difference in hydroxyproline and elastin content compared with native PA. Our long-term results of cell-free tissue-engineering of PAs have revealed the acceptable qualities and characteristics of iTEV-PAs. The strategy of using this cell-free Biodegradable Scaffold to create relatively small PAs could be applicable in pediatric cardiovascular surgery requiring materials.

  • Abstract 13153: Long-Term Results of Cell-Free Biodegradable Scaffolds for In Situ Tissue-Engineering Pulmonary Artery in a Canine Model
    Circulation, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kenji Yamazaki
    Abstract:

    We have previously developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV) in a canine IVC model. We assessed the hy...

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model.
    PloS one, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.51±0.19 mmHg. The length of the iTEV at 2 years had increased by 0.48±0.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascular surgery involving biocompatible materials.

  • Longterm results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
    2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90 % of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascula

Yoshito Ikada - One of the best experts on this subject based on the ideXlab platform.

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue engineering of pulmonary artery in a canine model
    Biomaterials, 2013
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kensuke Taki, Kenji Yamazaki
    Abstract:

    We previously developed a cell-free, Biodegradable Scaffold for in-situ tissue-engineering vasculature (iTEV) in a canine inferior vena cava (IVC) model. In this study, we investigated application of this Scaffold for iTEV of the pulmonary artery (iTEV-PA) in a canine model. In vivo experiments were conducted to determine Scaffold characteristics and long-term efficacy. Biodegradable Scaffolds comprised polyglycolide knitted fibers and an l-lactide and e-caprolactone copolymer sponge, with an outer glycolide and e-caprolactone copolymer monofilament reinforcement. Tubular Scaffolds (8 mm diameter) were implanted into the left pulmonary artery of experimental animals (n = 7) and evaluated up to 12 months postoperatively. Angiography of iTEV-PA after 12 months showed a well-formed vasculature without marked stenosis, aneurysmal change or thrombosis of iTEV-PA. Histological analysis revealed a vessel-like vasculature without calcification. However, vascular smooth muscle cells were not well-developed 12 months post-implantation. Biochemical analyses showed no significant difference in hydroxyproline and elastin content compared with native PA. Our long-term results of cell-free tissue-engineering of PAs have revealed the acceptable qualities and characteristics of iTEV-PAs. The strategy of using this cell-free Biodegradable Scaffold to create relatively small PAs could be applicable in pediatric cardiovascular surgery requiring materials.

  • Abstract 13153: Long-Term Results of Cell-Free Biodegradable Scaffolds for In Situ Tissue-Engineering Pulmonary Artery in a Canine Model
    Circulation, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Yuki Sakamoto, Yoshito Ikada, Kenji Yamazaki
    Abstract:

    We have previously developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV) in a canine IVC model. We assessed the hy...

  • Long-term results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model.
    PloS one, 2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90% of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.51±0.19 mmHg. The length of the iTEV at 2 years had increased by 0.48±0.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascular surgery involving biocompatible materials.

  • Longterm results of cell-free Biodegradable Scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
    2012
    Co-Authors: Goki Matsumura, Noriko Isayama, Shojiro Matsuda, Kenji Yamazaki, Yuki Sakamoto, Naotaka Nitta, Yoshito Ikada
    Abstract:

    We have developed a new Biodegradable Scaffold that does not require any cell seeding to create an in-situ tissue-engineering vasculature (iTEV). Animal experiments were conducted to test its characteristics and long-term efficacy. An 8-mm tubular Biodegradable Scaffold, consisting of polyglycolide knitted fibers and an L-lactide and e-caprolactone copolymer sponge with outer glycolide and e-caprolactone copolymer monofilament reinforcement, was implanted into the inferior vena cava (IVC) of 13 canines. All the animals remained alive without any major complications until euthanasia. The utility of the iTEV was evaluated from 1 to 24 months postoperatively. The elastic modulus of the iTEV determined by an intravascular ultrasound imaging system was about 90 % of the native IVC after 1 month. Angiography of the iTEV after 2 years showed a well-formed vasculature without marked stenosis or thrombosis with a mean pressure gradient of 0.5160.19 mmHg. The length of the iTEV at 2 years had increased by 0.4860.15 cm compared with the length of the original Scaffold (2–3 cm). Histological examinations revealed a well-formed vessel-like vasculature without calcification. Biochemical analyses showed no significant differences in the hydroxyproline, elastin, and calcium contents compared with the native IVC. We concluded that the findings shown above provide direct evidence that the new Scaffold can be useful for cell-free tissue-engineering of vasculature. The long-term results revealed that the iTEV was of good quality and had adapted its shape to the needs of the living body. Therefore, this Scaffold would be applicable for pediatric cardiovascula